Safety Shot Inc (SHOT)
USD 0.48
(-9.45%)
USD 0.48
(-9.45%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.89 Million USD | -22.55% |
| 2022 | 5.02 Million USD | 121.86% |
| 2021 | 2.26 Million USD | 6.24% |
| 2020 | 2.13 Million USD | 481.6% |
| 2019 | 366.58 Thousand USD | 5136.87% |
| 2018 | 7000.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.64 Million USD | -6.36% |
| 2024 Q2 | 4.22 Million USD | 15.94% |
| 2023 Q3 | 4.62 Million USD | -14.58% |
| 2023 Q1 | 5.09 Million USD | 1.46% |
| 2023 Q2 | 5.41 Million USD | 6.13% |
| 2023 FY | 3.89 Million USD | -22.55% |
| 2023 Q4 | 3.89 Million USD | -15.8% |
| 2022 Q1 | 1.64 Million USD | -27.56% |
| 2022 FY | 5.02 Million USD | 121.86% |
| 2022 Q4 | 5.02 Million USD | 42.41% |
| 2022 Q3 | 3.52 Million USD | -4.36% |
| 2022 Q2 | 3.68 Million USD | 124.85% |
| 2021 Q2 | 2.6 Million USD | 300.7% |
| 2021 Q3 | 1.82 Million USD | -30.14% |
| 2021 Q4 | 2.26 Million USD | 24.33% |
| 2021 FY | 2.26 Million USD | 6.24% |
| 2021 Q1 | 650.75 Thousand USD | -69.48% |
| 2020 Q4 | 2.13 Million USD | -16.62% |
| 2020 Q2 | 2.29 Million USD | 18.71% |
| 2020 Q1 | 1.93 Million USD | 427.47% |
| 2020 FY | 2.13 Million USD | 481.6% |
| 2020 Q3 | 2.55 Million USD | 11.39% |
| 2019 FY | 366.58 Thousand USD | 5136.87% |
| 2019 Q4 | 366.58 Thousand USD | 0.0% |
| 2019 Q2 | 43.73 Thousand USD | 53.26% |
| 2019 Q1 | 28.53 Thousand USD | 0.0% |
| 2018 FY | 7000.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 99.175% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 97.625% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.589% |
| Cosmos Health Inc. | 30.25 Million USD | 87.135% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 54.16% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 99.411% |
| Cronos Group Inc. | 43.73 Million USD | 91.101% |
| Incannex Healthcare Limited | 5.83 Million USD | 33.241% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 91.966% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 98.229% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -1673.044% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | 36.608% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | 36.608% |
| SCYNEXIS, Inc. | 55.45 Million USD | 92.981% |
| Theratechnologies Inc. | 98.63 Million USD | 96.054% |
| Alpha Teknova, Inc. | 38.55 Million USD | 89.904% |
| Universe Pharmaceuticals INC | 13.75 Million USD | 71.703% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 99.447% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | 55.55% |
| Dynavax Technologies Corporation | 375.02 Million USD | 98.962% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 99.524% |
| Radius Health, Inc. | 804.29 Million USD | 99.516% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | 57.68% |
| Alvotech | 1.88 Billion USD | 99.793% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 97.156% |
| SIGA Technologies, Inc. | 57.97 Million USD | 93.287% |
| Shineco, Inc. | 47.6 Million USD | 91.824% |
| Silver Spike Investment Corp. | 3 Million USD | -29.311% |
| Journey Medical Corporation | 56.49 Million USD | 93.111% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 81.741% |
| Embecta Corp. | 2.03 Billion USD | 99.809% |
| Harrow Health, Inc. | 241.75 Million USD | 98.39% |
| Procaps Group, S.A. | 462.06 Million USD | 99.158% |
| Biofrontera Inc. | 23.13 Million USD | 83.18% |
| DURECT Corporation | 30.4 Million USD | 87.2% |
| PainReform Ltd. | 2.69 Million USD | -44.632% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 99.202% |
| OptiNose, Inc. | 194.33 Million USD | 97.997% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 81.447% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 97.854% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 92.589% |
| ProPhase Labs, Inc. | 42.54 Million USD | 90.852% |
| Phibro Animal Health Corporation | 725.54 Million USD | 99.464% |
| Procaps Group S.A. | 462.06 Million USD | 99.158% |
| TherapeuticsMD, Inc. | 14.02 Million USD | 72.243% |
| Viatris Inc. | 27.21 Billion USD | 99.986% |
| Rockwell Medical, Inc. | 30.88 Million USD | 87.397% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 95.694% |
| Tilray Brands, Inc. | 892.11 Million USD | 99.564% |
| PetIQ, Inc. | 645.22 Million USD | 99.397% |
| Talphera, Inc. | 6.29 Million USD | 38.123% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.618% |
| Alimera Sciences, Inc. | 107.35 Million USD | 96.375% |
| Assertio Holdings, Inc. | 148.41 Million USD | 97.378% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -105.28% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 97.755% |
| Hempacco Co., Inc. | 18.82 Million USD | 79.322% |
| Alvotech | 1.88 Billion USD | 99.793% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 99.534% |
| Kamada Ltd. | 109.96 Million USD | 96.461% |
| Currenc Group, Inc. | 177.67 Million USD | 97.809% |
| Indivior PLC | 1.95 Billion USD | 99.801% |
| Evoke Pharma, Inc. | 9.64 Million USD | 59.66% |
| Flora Growth Corp. | 17.22 Million USD | 77.401% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 54.16% |
| Evolus, Inc. | 209.68 Million USD | 98.144% |
| HUTCHMED (China) Limited | 536.38 Million USD | 99.274% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 99.554% |
| Akanda Corp. | 12.66 Million USD | 69.279% |